Michel Dard, DDS, MS, PhD, CEO of BioCellgraft, blends science, strategy, and empathy to advance regenerative dentistry, pioneering minimally invasive solutions while championing momentum, loyalty, and user-centred innovation worldwide.
When Michel Dard reflects on his career, a thread of curiosity, courage, and conviction runs through every chapter. From his early training as a dentist in France and oral surgeon in the United States, through to senior roles in academia, hospitals, and global corporations, he has consistently followed the pull of exploration. Today, as CEO of BioCellgraft, Dard is channeling decades of experience into advancing regenerative solutions that promise to reshape clinical practice in dentistry and beyond.
“I was always curious to explore different facets of my profession,” he recalls. “When I first encountered the pharmaceutical industry in the 1990s while working at Merck, I was seduced by the scientific, very dynamic environment and the broad spectrum of career opportunities. It showed me that research and innovation could reach far beyond the clinic.”
Defining Moments and Mentors
Dard’s journey was not a straight line but a series of defining moments, each reinforcing his appetite for innovation and leadership.
“In 1991, I became Member and Chairman of INSERM Specialised Medical Societies at the National Institute of Health and Medical Research in Paris. That was the first time I realised the responsibility and influence that comes with guiding scientific communities,” he says.
A second milestone came in 1996, when he was nominated as an Expert at the European Union Commission in Brussels, tasked with shaping research and innovation policy. “It was humbling, and also taught me that science has to sit within a broader societal and regulatory context if it is to make a real impact,” he explains.
That same year, another formative influence entered his professional life. “I joined the team of Hans Reimer, CEO of Biomet-Merck in Germany. Hans was a seasoned leader with a strong ability to listen. Working alongside him, I began to appreciate the nuances of leadership; not only setting direction but also truly hearing people.”
Years later, another CEO would leave an indelible mark. “In 2015, I worked closely with Marco Gadola at Straumann Group. Marco was pragmatic, always defining clear business objectives. He never gave up, and from him I learned how to scrutinise a market and take advantage of opportunities. That discipline is something I carry with me today.”
From Research to Real-World Impact
Dard is both prolific and pragmatic. With more than 200 peer-reviewed publications, book chapters, and proceedings, alongside numerous patents, he has contributed extensively to the body of scientific knowledge. Yet he insists that research alone is not enough.
“The research process is about gathering and organising discovery and knowledge. It’s intellectual, and it is not time-dependent,” he explains. “But a successful product fulfils a need in daily life. It improves quality of life, and it is very much time-dependent.”
To illustrate, he points to something as ordinary as a trouser belt. “You could publish fascinating research on the belt — from mathematics to chemistry, medicine, or history — but if it cannot actually hold up your trousers, you look embarrassed and even ridiculous. Success lies in usability and demographics — how many people want it, and how many people can use it.”
Among his achievements, Dard highlights a method he documented in his 2023 book Surgical Research in Implant Dentistry. “The first chapter is entitled The Method Sets the Tone. For me, that’s the foundation: rigorous methods that can be translated into solutions with business potential.”
Still, he hints that the innovation he is proudest of is the one yet to come. “The most exciting achievements are always in the pipeline, waiting to be brought to life.”
Dard adds that it must be kept in mind that from the conception of a project to its full completion, the leader and each team member must “think out of the box” individually and as a cohesive group in all circumstances. This courageous attitude will always pay back.
The BioCellgraft Pipeline: Regeneration with Purpose
That pipeline today includes BioCellgraft’s flagship regenerative solutions: OraFyl, OraFyl M, and OraFyl 3L. Each product originates from the human placenta and is designed to address soft and hard tissue defects with a minimally invasive approach.
“OraFyl is a dual and flowable regenerative solution, extracted from the chorionic part of the placenta. It is a highly purified macromolecular assembly of collagen I and elastin, with no cross-linkers or adjuvants,” Dard explains. “OraFyl M is a decellularised, dehydrated amniotic membrane for soft tissue protection, while OraFyl 3L is a multilayer amniotic barrier membrane for soft tissue support.”
The key, he says, is respecting the natural properties of the raw material. “The chorion can be transformed into a gel, while the amnion is a membrane with unique elasticity and mechanical properties. We designed our processes to preserve those qualities.”
The products are not only complementary but also transformative in their versatility. “Because of OraFyl, already-marketed bone substitute materials can become osteoinductive when mixed, enhancing bone regeneration. Soft tissue outcomes are also transformational when OraFyl is injected correctly,” he says.
What sets BioCellgraft apart, according to Dard, is its strict adherence to design thinking principles. “We use a user-centred, iterative process to creatively solve complex problems. We question assumptions, redefine problems, and create innovative solutions with the user at the heart. That’s why our products deliver high usability, versatility across 10 surgical indications, and are training-friendly. And importantly, our clinical partners — not just the so-called KOLs — play an essential role in development.”
Leadership with Momentum and Loyalty
Dard’s approach to leadership is shaped as much by his time in the French Marines as by his decades in the boardroom. “In the army, the maxim was: Never leave a man behind. That is fully valid in the corporate world too. It means teamwork, loyalty, and cohesion,” he says.
As CEO, he sees his role in simple but powerful terms. “A CEO must be curious, courageous, and permanently vigilant. The responsibility is to set up and keep the momentum. If you lose momentum, you lose the company.”
That sense of vigilance is coupled with empathy for his teams. “Leadership is about listening, about holding the line, and about ensuring that no one is left behind.”
Bridging Science and Business
For the next generation of scientists and entrepreneurs, Dard has clear advice: combine technical depth with market awareness. “Learn as much as you can about the technology, even the most fundamental aspects,” he urges. “But also conduct serious market research. The key question is: is there a market? Then define your customer persona. Who is ready to pay?”
Having worked across Europe and the United States, he also recognises cultural differences in how innovation is supported. “In the US, it is company-driven. Businesses are involved from the start and commit financially, which shortens the path to commercialisation. In Europe, there are grants at the national and European level, which are valuable but slower. Both models have strengths, but for speed and scale, the US has an advantage.”
Purpose and Legacy
After decades of influence in academia, biotech, and dentistry, what continues to drive Dard is not prestige or patents, but people. “What motivates me is helping my fellow dentists to do a better job; treating their patients faster, safely, and efficiently,” he says.
His legacy, he hopes, will be measured in the success of practitioners and the outcomes for patients. “At BioCellgraft, we are creating tools that allow clinicians to do what they do best — heal. If my work helps them achieve that with greater ease and better results, then I have succeeded.”
A Leader at the Crossroads of Science and Humanity
Michel Dard’s journey illustrates the delicate balance between scientific discovery and practical innovation, between leadership discipline and human compassion. From Paris to Basel, academia to biotech, research to boardroom, he has continually asked not just what science can discover, but how it can serve.
“Innovation is not just about creating something new,” he reflects. “It’s about creating something that matters.”
As the first dentist in the history of Business Worldwide Magazine to be awarded this prestigious prize, Dard’s contribution to his industry is a significant one. News of the accolade will be shared in the international professional journal “Dental Tribune International” (HQ in Leipzig, Germany), which has subsidiaries all over the world.Learn more about BioCellgraft at https://biocellgraft.com/















